Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial
The ZEUS clinical trial found that the anti-inflammatory drug ziltivekimab did not reduce major cardiovascular events in high-risk patients.
10 trends tracked about this subject — the full history, oldest to newest below.
The ZEUS clinical trial found that the anti-inflammatory drug ziltivekimab did not reduce major cardiovascular events in high-risk patients.
Coverage from Medical Daily, MedCentral, and pharmaphorum details findings on SGLT2 inhibitors at ASN Kidney Week 2026.
New data presented at ASN indicates SGLT2 inhibitors improve survival and cognitive function for elderly patients with chronic kidney disease.
A ten-year study links fruit and vegetable consumption to reduced hospitalizations for kidney patients.
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
Novo Nordisk has terminated two additional phase 3 trials of its cardiovascular drug ziltivekimab due to futility, impacting its growth strategy.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Health experts and medical outlets are highlighting specific dietary choices and lifestyle habits to combat chronic kidney disease and diabetic damage.
Medical and lifestyle guidance regarding kidney health is currently trending across multiple health and news platforms.